Data as of Aug 28
| -0.28 / -2.98%|
The 3 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 18.50, with a high estimate of 25.00 and a low estimate of 15.00. The median estimate represents a +102.63% increase from the last price of 9.13.
The current consensus among 3 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.